Bulk Inquiry
CCT 007093
Axon 1821
CAS:
176957-55-4
Purity:
99%
- Moderately soluble in DMSO
- MF: C15H12OS2
- MW: 272.39
Description
An effective PPM1D inhibitor that selectively reduces viability of human tumour cell lines; apoptosis inducer
More Information
| Parent CAS No. | 176957-55-4 |
|---|---|
| Chemical Name | (2E,5E)-2,5-bis(thiophen-2-ylmethylene)cyclopentanone |
| SMILES | C1(=O)/C(=C/C2SC=CC=2)/CC/C/1=CC1SC=CC=1 |
| MFCD | MFCD00121546 |
| InChi | InChI=1S/C15H12OS2/c16-15-11(9-13-3-1-7-17-13)5-6-12(15)10-14-4-2-8-18-14/h1-4,7-10H,5-6H2/b11-9+,12-10+ |
| InChiKey | KPFZCKDPBMGECB-WGDLNXRISA-N |
| CID | 2314623 |
| Short Description | PPM1D inhibitor |
References
- S Rayter et al. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D Oncogene. 2008, 27(8), 1036-1044.
- J Pärssinen et al. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. Cancer Gene Ther. 2008, 182(1), 33-39.
- DSP Tan et al. PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas. Clin. Cancer Res. 2009, 15, 2269.
- JA Bauer et al. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res. 2010, 12(3), R41.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1134 | RO 28-0450 |
From $143.00 |
| 1355 | RO 28-1674 |
From $143.00 |
| 1356 | RO 28-1675 |
From $115.50 |
| 2178 | BCI |
From $82.50 |
| 2186 | SF 1670 |
From $132.00 |
| 2263 | Tacrolimus |
From $110.00 |
| 2524 | Sephin 1 |
From $60.50 |
| 2633 | SHP099 |
From $88.00 |
| 2852 | BCI hydrochloride |
From $82.50 |
| 2963 | SBI-425 |
From $137.50 |
| 3680 | LockdownPro |
From $99.00 |
| 3994 | GSK2830371 |
From $132.00 |
Other Categories
Get a Quote for
Loading...